Home / Business and Economy / Lupin Under Tax Probe: Financials Unscathed
Lupin Under Tax Probe: Financials Unscathed
25 Feb
Summary
- Maharashtra's GST Department initiated inspection at Lupin's registered office.
- Company assures no impact on financials, operations, or other activities.
- Lupin reported strong Q3 FY26 growth with record US sales.
Maharashtra's Goods & Services Tax Department has initiated inspection and search proceedings at the registered office of the pharmaceutical company Lupin.
In a recent statement, Lupin assured that these ongoing investigations will not have any discernible impact on the company's financial performance, day-to-day operations, or other business functions.
This development follows a period of strong financial results for Lupin, which reported its highest-ever quarterly sales in the United States and experienced double-digit growth in India during the third quarter of fiscal year 2026.
The company's India sales reached Rs 20,387 million, contributing 29% to global sales, while the United States remains its largest market, accounting for 44% of sales at Rs 31,132 million in Q3 FY26.
Lupin also invested Rs 5,352 million in research and development during the quarter, representing 7.5% of its sales.
